Furazolidone, amoxicillin and omeprazole with or without bismuth for eradication of Helicobacter pylori in peptic ulcer disease

Ghadir, Mohammad Reza; Shafaghi, Afshin; Iranikhah, Abolfazl; Pakdin, A; Joukar, Farahnaz; Ghanaei, F Mansour

doi:10.4318/tjg.2011.0148

Cited by 19 publications

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Furazolidone, an Underutilized Drug for H. pylori Eradication: Lessons from Iran

et al. 2017

View full text Add to dashboard Cite

Background Treatment success of H. pylori eradication therapy has declined worldwide largely because of increased antimicrobial resistance. New therapeutic approaches are needed, especially for countries like Iran, where resistance to commonly used drugs is already widespread and traditional H. pylori therapies produce poor cure rates. Aim to review the results of quadruple therapy trials containing bismuth and furazolidone in Iran. Methods We searched PubMed, Google scholar as well as the references of all published papers for studies done in Iran, utilizing furazolidone in the treatment of H. pylori infections. The target population was 4 drug studies that utilized a combination of bismuth, furazolidone, amoxicillin, or tetracycline plus a proton pump inhibitor. Results Eighteen studies with 22 arms including 1713 subjects were found. The weighted mean cure rate for 14-day studies (6 studies) using 200 mg b.i.d. furazolidone was 80% intention-to-treat (ITT) and 87% per protocol (PP). Studies using 100 mg b.i.d (3 studies) were less effective (weighted mean ITT cure rate = 67%). One small 14 day study with furazolidone 100 mg q.i.d. achieved cure rates of 94.5% ITT and PP. Conclusions Although furazolidone-bismuth quadruple therapy proved relatively effective in Iran, furazolidone-containing regimens remain to be optimized. Based on these data and results from China, it appears likely that 14 day therapy containing furazolidone 100 mg t.i.d. or q.i.d. is likely to provide the highest cure rates with lowest side effects; this remains to be experimentally tested. Detailed suggestions for further development of furazolidone-containing regimens are provided.

show abstract

Furazolidone, an Underutilized Drug for H. pylori Eradication: Lessons from Iran

et al. 2017

View full text Add to dashboard Cite

show abstract

An Update on 13C-Breath Tests: The Transition to Acceptability into Clinical Practice

Modak

2013

Volatile Biomarkers

View full text Add to dashboard Cite

Management of antibiotic-resistantHelicobacter pyloriinfection: current perspective in Iran

Alihosseini

Ghotaslou

Heravi

et al. 2020

Journal of Chemotherapy

View full text Add to dashboard Cite

Furazolidone, amoxicillin and omeprazole with or without bismuth for eradication of Helicobacter pylori in peptic ulcer disease

Abstract: (S›ras›yla, amoksisilin, furazolidon, omeprazol, bizmut ve amoksisilin, furazolidon, omeprazol rejimleri

Cited by 19 publications

References 16 publications

Furazolidone, an Underutilized Drug for H. pylori Eradication: Lessons from Iran

Furazolidone, an Underutilized Drug for H. pylori Eradication: Lessons from Iran

An Update on 13C-Breath Tests: The Transition to Acceptability into Clinical Practice

Management of antibiotic-resistantHelicobacter pyloriinfection: current perspective in Iran

Contact Info

Product

Resources

About